First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations.
Fahd BenjellounZeliha OrucNicole M ThielensBernard VerrierGael ChampierNadine VincentNicolas RochereauAlexandre GirardFabienne JospinBlandine ChanutChristian GeninMichel CognéStephane PaulPublished in: Journal of immunology (Baltimore, Md. : 1950) (2016)
Mucosal HIV-1-specific IgA have been described as being able to neutralize HIV-1 and to block viral transcytosis. In serum and saliva, the anti-HIV IgA response is predominantly raised against the envelope of HIV-1. In this work, we describe the in vivo generation of gp41-specific IgA1 in humanized α1KI mice to produce chimeric IgA1. Mice were immunized with a conformational immunogenic gp41-transfected cell line. Among 2300 clones screened by immunofluorescence microscopy, six different gp41-specific IgA with strong recognition of gp41 were identified. Two of them have strong neutralizing activity against primary HIV-1 tier 1, 2, and 3 strains and present a low rate of somatic mutations and autoreactivity, unlike what was described for classical gp41-specific IgG. Epitopes were identified and located in the hepted repeat 2/membrane proximal external region. These Abs could be of interest in prophylactic treatment to block HIV-1 penetration in mucosa or in chronically infected patients in combination with antiretroviral therapy to reduce viral load and reservoir.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- hiv testing
- hiv aids
- hiv infected patients
- hepatitis c virus
- men who have sex with men
- high resolution
- type diabetes
- sars cov
- radiation therapy
- escherichia coli
- gene expression
- squamous cell carcinoma
- blood brain barrier
- stem cells
- adipose tissue
- cell therapy
- high throughput
- molecular dynamics simulations
- neoadjuvant chemotherapy
- mass spectrometry
- multiple myeloma
- optical coherence tomography